STOCK TITAN

Performant Financial Corporation Announces Financial Results for First Quarter 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Performant Financial Corporation (Nasdaq: PFMT) reported Q1 2022 financial results with total revenues of $27.1 million, a 14% decline from $31.4 million in the prior year. Healthcare revenues grew by 76% to $23.4 million, driven by strong performance in claims-based and eligibility-based services. Despite a net loss of $1.7 million, an improvement from $4.4 million a year ago, adjusted EBITDA increased to $0.3 million. The company anticipates healthcare revenues to reach $92-$96 million in 2022, amid potential challenges from COVID-19 variants.

Positive
  • Healthcare revenues increased by 76%, reaching $23.4 million.
  • Improved net loss of $1.7 million, compared to $4.4 million last year.
  • Adjusted EBITDA turned positive at $0.3 million, up from a negative $0.2 million.
Negative
  • Total revenues decreased by 14%, down from $31.4 million in the prior year.
  • Recovery revenues declined by 99%, falling to $0.1 million from $14.5 million.

LIVERMORE, Calif.--(BUSINESS WIRE)-- Performant Financial Corporation (Nasdaq: PFMT) (the "Company"), a leading provider of technology-enabled audit, recovery, and related analytics services in the United States with a focus in the healthcare payment integrity services industry, today reported the following financial results for its first quarter ended March 31, 2022:

First Quarter Financial Highlights

  • Total revenues of $27.1 million, compared to revenues of $31.4 million in the prior year period.
  • Healthcare revenues of $23.4 million, compared to $13.3 million in the prior year period, an increase of 76%
  • Net loss of approximately $1.7 million, or $(0.02) per diluted share, compared to net loss of $4.4 million, or $(0.08) per diluted share, in the prior year period.
  • Adjusted net loss was $1.1 million, or $(0.02) per diluted share, compared to adjusted net loss of $2.8 million, or $(0.05) per diluted share, in the prior year period.
  • Adjusted EBITDA of $0.3 million, compared to $(0.2) million in the prior year period.

First Quarter 2022 Results

Total revenues in the first quarter were $27.1 million, a decrease of $4.3 million, or 14% from revenues of $31.4 million in the prior year period. Excluding the $14.5 million that we reported in the first quarter of 2021 from our shuttered Recovery markets business, total revenues grew over 60% year-over-year. Healthcare revenues in the first quarter of 2022 were $23.4 million, an increase of $10.1 million, or 76%, from revenues of $13.3 million in the prior year period. Within Healthcare, claims-based services revenue in the first quarter of 2022 was $9.1 million, while revenue from eligibility-based services in the first quarter was $14.2 million.

“In the first quarter we reported our strongest ever first quarter for healthcare revenues driven by the continued growth from our fully implemented SOWs as well as the contribution from some of the 33 program implementations that we've announced over the past five quarters,” stated Simeon Kohl, President of Performant. “In addition, we were awarded the HHS OIG IDIQ Contract for Medical Review and Consultative Services as well as the award for Region 2 of the Medicare Fee for Service Recovery Audit Program, but we anticipate a delay before the latter contract kicks off as the award is currently under review by CMS related to the incumbent contractor’s protest.”

Recovery revenues in the first quarter were $0.1 million, a decrease of $14.4 million, or 99%, from revenues of $14.5 million in the prior year period. Revenues from our Customer Care / Outsourced Services in the first quarter were $3.6 million, flat when compared to the prior year period.

Net loss for the first quarter was $1.7 million, or $(0.02) per share on a diluted basis, compared to a net loss of $4.4 million, or $(0.08) per share on a diluted basis, in the prior year period. Adjusted net loss for the first quarter was $1.1 million, or $(0.02) per share on a diluted basis, compared to adjusted net loss of $2.8 million, or $(0.05) per diluted share, in the prior year period. Adjusted EBITDA for the first quarter was $0.3 million as compared to $(0.2) million in the prior year period.

As of March 31, 2022, the Company had cash, cash equivalents, and restricted cash of approximately $19.6 million.

“Given our achievements in the first quarter and known opportunities ahead of us that we believe we can execute upon, we are quite pleased with how we are tracking toward both the current year expectations and more importantly, our long term goals. We remain optimistic about improving trends in core utilization and the return to normal from COVID but acknowledge that COVID variant uncertainty and uncertainty in the macro affairs of an ever connected world may impact utilization rates. That said, we are pleased to amend our current views on Healthcare revenue and believe that we can achieve $92-$96MM in Healthcare market revenues in 2022, with Customer Care market revenues being flat to slightly down. We are leaving our EBITDA guidance intact at $2-$4 million for 2022 until we can gain further clarity on the timing and ramp-speed of the RAC Region 2 contract to provide a more informed update,” stated Rohit Ramchandani, Senior Vice President of Finance and Strategy at Performant.

Note Regarding Use of Non-GAAP Financial Measures

In this press release, to supplement our consolidated financial statements, the Company presents adjusted EBITDA, adjusted net income (loss), and adjusted net income (loss) per diluted share. These measures are not in accordance with accounting principles generally accepted in the United States of America (US GAAP) and accordingly reconciliations of adjusted EBITDA and adjusted net income (loss) to net income (loss) determined in accordance with US GAAP are included in the “Reconciliation of Non-GAAP Results” table at the end of this press release. We have included adjusted EBITDA and adjusted net income (loss) in this press release because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA and adjusted net income (loss) provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA and adjusted net income (loss) has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses, that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

Earnings Conference Call

The Company will hold a conference call to discuss its first quarter 2022 results today at 5:00 p.m. Eastern. A live webcast of the call may be accessed on the Investor Relations section of the Company’s website at investors.performantcorp.com. The conference call is also available by dialing 844-826-3033 (domestic) or 412-317-5185 (international).

A replay of the call will be available on the Company's website or by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 10166578. The telephonic replay will be available approximately three hours after the call, through May 16, 2022.

About Performant Financial Corporation

Performant is a leading provider of technology-enabled audit, recovery, and analytics services in the United States with a focus in the healthcare payment integrity industry. Performant works with healthcare payers through claims auditing and eligibility-based (also known as coordination-of-benefits) services to identify improper payments. The Company engages clients in both government and commercial markets. The Company also has a call center which serves clients with complex consumer engagement needs. Clients of the Company typically operate in complex and highly regulated environments and contract for their payment integrity needs in order to reduce losses on improper healthcare payments.

Powered by a proprietary analytic platform and workflow technology, Performant also provides professional services related to the recovery effort, including reporting capabilities, support services, customer care and stakeholder training programs meant to mitigate future instances of improper payments. Founded in 1976, Performant is headquartered in Livermore, California.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), and adjusted EBITDA in 2022 and beyond. These forward-looking statements are based on current expectations, estimates, assumptions and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the material adverse impact of the COVID-19 pandemic on the Company's business, results of operations and financial condition as well as on the business operations and financial performance of many of its customers, that the Company faces a long period to implement a new contract which may result in the incurring of expenses before the receipt of revenues from new client relationships, that downturns in domestic or global economic conditions and other macroeconomic factors could harm the Company’s business and results of operations, that the Company may not have sufficient cash flows from operations to fund ongoing operations and other liquidity needs, that the high level of revenue concentration among the Company's largest customers and any termination in the Company’s relationship with any of its significant clients would result in a material decline in revenues, that many of the Company's customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes and may be changed or terminated unilaterally and on short notice, that the Company may not be able to manage its potential growth effectively, that the Company faces significant competition in all of its markets, that limitations on the scope of the Company's audit activity under its claims audit contracts may reduce revenue opportunities, that the U.S. federal government accounts for a significant portion of the Company's revenues, that the Company’s indebtedness could adversely affect its business and financial condition and could reduce the funds available for other purposes and the failure to comply with covenants contained in its credit agreement could result in an event of default that could adversely affect its results of operations, that future legislative and regulatory changes may have significant effects on the Company's business, that failure of the Company's or third parties' operating systems and technology infrastructure could disrupt the operation of the Company's business and the threat of breach of the Company's security measures or failure or unauthorized access to confidential data that the Company possesses. More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2021 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except per share amounts)

 

 

March 31,

2022

 

December 31,

2021

 

(Unaudited)

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

17,432

 

 

$

17,347

 

Restricted cash

 

2,203

 

 

 

2,203

 

Trade accounts receivable, net of allowance for doubtful accounts of $29 and $—, respectively

 

19,837

 

 

 

20,808

 

Contract assets

 

8,875

 

 

 

8,113

 

Prepaid expenses and other current assets

 

3,941

 

 

 

3,077

 

Income tax receivable

 

3,085

 

 

 

3,159

 

Total current assets

 

55,373

 

 

 

54,707

 

Property, equipment, and leasehold improvements, net

 

15,306

 

 

 

15,708

 

Goodwill

 

47,372

 

 

 

47,372

 

Right-of-use assets

 

2,760

 

 

 

3,235

 

Other assets

 

965

 

 

 

963

 

Total assets

$

121,776

 

 

$

121,985

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Current maturities of notes payable, net of unamortized debt issuance costs of $13 and $11, respectively

$

612

 

 

$

489

 

Accrued salaries and benefits

 

5,935

 

 

 

8,476

 

Accounts payable

 

1,191

 

 

 

1,124

 

Other current liabilities

 

1,762

 

 

 

3,732

 

Contract liabilities

 

773

 

 

 

634

 

Estimated liability for appeals and disputes

 

1,471

 

 

 

1,190

 

Lease liabilities

 

1,528

 

 

 

1,862

 

Total current liabilities

 

13,272

 

 

 

17,507

 

Notes payable, net of current portion and unamortized debt issuance costs of $392 and $416, respectively

 

18,858

 

 

 

19,084

 

Lease liabilities

 

1,601

 

 

 

1,803

 

Other liabilities

 

1,174

 

 

 

1,168

 

Total liabilities

 

34,905

 

 

 

39,562

 

Commitments and contingencies (note 3 and note 4)

 

 

 

Stockholders’ equity:

 

 

 

Common stock, $0.0001 par value. Authorized, 500,000 shares at March 31, 2022 and December 31, 2021 respectively; issued and outstanding 73,144 and 69,281 shares at March 31, 2022 and December 31, 2021, respectively

 

7

 

 

 

7

 

Additional paid-in capital

 

139,783

 

 

 

133,662

 

Accumulated deficit

 

(52,919

)

 

 

(51,246

)

Total stockholders’ equity

 

86,871

 

 

 

82,423

 

Total liabilities and stockholders’ equity

$

121,776

 

 

$

121,985

 

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

 

 

Three Months Ended

March 31,

 

 

2022

 

2021

Revenues

 

$

27,083

 

 

$

31,390

 

Operating expenses:

 

 

 

 

Salaries and benefits

 

 

20,439

 

 

 

24,090

 

Other operating expenses

 

 

8,131

 

 

 

10,356

 

Total operating expenses

 

 

28,570

 

 

 

34,446

 

Loss from operations

 

 

(1,487

)

 

 

(3,056

)

Interest expense

 

 

(155

)

 

 

(1,346

)

Loss before provision for income taxes

 

 

(1,642

)

 

 

(4,402

)

Provision for income taxes

 

 

31

 

 

 

37

 

Net loss

 

$

(1,673

)

 

$

(4,439

)

Net loss per share

 

 

 

 

Basic

 

$

(0.02

)

 

$

(0.08

)

Diluted

 

$

(0.02

)

 

$

(0.08

)

Weighted average shares

 

 

 

 

Basic

 

 

69,873

 

 

 

54,813

 

Diluted

 

 

69,873

 

 

 

54,813

 

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

Three Months Ended

March 31,

 

2022

 

2021

Cash flows from operating activities:

 

 

 

Net loss

$

(1,673

)

 

$

(4,439

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

Loss (gain) on disposal of assets and impairment of long-lived assets

 

(17

)

 

 

636

 

Depreciation and amortization

 

1,102

 

 

 

1,016

 

Right-of-use assets amortization

 

475

 

 

 

507

 

Stock-based compensation

 

558

 

 

 

649

 

Interest expense from debt issuance costs

 

24

 

 

 

369

 

Changes in operating assets and liabilities:

 

 

 

Trade accounts receivable

 

971

 

 

 

2,616

 

Contract assets

 

(762

)

 

 

(283

)

Prepaid expenses and other current assets

 

(864

)

 

 

117

 

Income tax receivable

 

74

 

 

 

60

 

Other assets

 

(2

)

 

 

85

 

Accrued salaries and benefits

 

(2,541

)

 

 

799

 

Accounts payable

 

67

 

 

 

458

 

Contract liabilities and other current liabilities

 

(1,815

)

 

 

(114

)

Estimated liability for appeals and disputes

 

281

 

 

 

3,359

 

Lease liabilities

 

(536

)

 

 

(591

)

Other liabilities

 

7

 

 

 

(422

)

Net cash (used in) provided by operating activities

 

(4,651

)

 

 

4,822

 

Cash flows from investing activities:

 

 

 

Purchase of property, equipment, and leasehold improvements

 

(700

)

 

 

(826

)

Proceeds from sale of certain recovery contracts

 

 

 

 

 

Net cash used in investing activities

 

(700

)

 

 

(826

)

Cash flows from financing activities:

 

 

 

Repayment of notes payable

 

(125

)

 

 

(863

)

Debt issuance costs paid

 

(2

)

 

 

 

Taxes paid related to net share settlement of stock awards

 

 

 

 

(23

)

Proceeds from exercise of warrants

 

5,563

 

 

 

 

Net cash provided by (used in) financing activities

 

5,436

 

 

 

(886

)

Net increase in cash, cash equivalents and restricted cash

 

85

 

 

 

3,110

 

Cash, cash equivalents and restricted cash at beginning of period

 

19,550

 

 

 

18,296

 

Cash, cash equivalents and restricted cash at end of period

$

19,635

 

 

$

21,406

 

Reconciliation of the Consolidated Statements of Cash Flows to the Consolidated Balance Sheets:

 

 

 

Cash and cash equivalents

$

17,432

 

 

$

19,203

 

Restricted cash

 

2,203

 

 

 

2,203

 

Total cash, cash equivalents and restricted cash at end of period

$

19,635

 

 

$

21,406

 

Supplemental disclosures of cash flow information:

 

 

 

Cash paid for income taxes

$

1

 

 

$

432

 

Cash paid for interest

$

176

 

 

$

977

 

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES

Reconciliation of Non-GAAP Results

(In thousands, except per share amount)

(Unaudited)

 

 

Three Months Ended

March 31,

 

 

2022

 

2021

 

 

(in thousands)

Adjusted EBITDA:

 

 

 

 

Net income (loss)

 

$

(1,673

)

 

$

(4,439

)

Provision for income taxes

 

 

31

 

 

 

37

 

Interest expense (1)

 

 

155

 

 

 

1,346

 

Stock-based compensation

 

 

558

 

 

 

649

 

Depreciation and amortization

 

 

1,102

 

 

 

1,016

 

Impairment of long-lived assets

 

 

 

 

 

636

 

Severance expenses (4)

 

 

142

 

 

 

 

Non-core operating expenses (5)

 

 

4

 

 

 

511

 

Adjusted EBITDA

 

$

319

 

 

$

(244

)

 

 

Three Months Ended

March 31,

 

 

2022

 

2021

 

 

(in thousands)

Adjusted Net Income (Loss):

 

 

 

 

Net income (loss)

 

$

(1,673

)

 

$

(4,439

)

Stock-based compensation

 

 

558

 

 

 

649

 

Amortization of intangible assets (2)

 

 

 

 

 

59

 

Amortization of debt issuance costs (3)

 

 

24

 

 

 

369

 

Impairment of long-lived assets

 

 

 

 

 

636

 

Severance expenses (4)

 

 

142

 

 

 

 

Non-core operating expenses (5)

 

 

4

 

 

 

511

 

Tax adjustments (6)

 

 

(200

)

 

 

(611

)

Adjusted net income (loss)

 

$

(1,145

)

 

$

(2,826

)

 

 

Three Months Ended

March 31,

 

 

2022

 

2021

 

 

(in thousands)

Adjusted Net Income (Loss) Per Diluted Share:

 

 

 

 

Net income (loss)

 

$

(1,673

)

 

$

(4,439

)

Plus: Adjustment items per reconciliation of adjusted net income (loss)

 

 

528

 

 

 

1,613

 

Adjusted net income (loss)

 

$

(1,145

)

 

$

(2,826

)

Adjusted net income (loss) per diluted share

 

$

(0.02

)

 

$

(0.05

)

Diluted average shares outstanding

 

 

69,873

 

 

 

54,813

 

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES

Reconciliation of Non-GAAP Results

(In thousands, except per share amount)

(Unaudited)

 

We are providing the following preliminary estimates of our financial results as follows:

 

 

 

Three Months

Ended

 

Nine Months Ending

 

Year Ended

 

Year Ending

 

 

March 31, 2022

 

December 31, 2022

 

December 31, 2021

 

December 31, 2022

 

 

Actual

 

Estimate

 

Actual

 

Estimate

Adjusted EBITDA:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(1,673

)

 

$

(3,827) to (5,827)

 

$

(10,288

)

 

$

(5,500) to (7,500)

Provision for income taxes

 

 

31

 

 

(381) to 719

 

 

62

 

 

(350) to 750

Interest expense (1)

 

 

155

 

 

845 to 1,345

 

 

11,313

 

 

1,000 to 1,500

Stock-based compensation

 

 

558

 

 

1,442 to 2,442

 

 

2,640

 

 

2,000 to 3,000

Depreciation and amortization

 

 

1,102

 

 

3,648 to 4,648

 

 

5,188

 

 

4,750 to 5,750

Impairment of long-lived assets

 

 

 

 

 

 

636

 

 

Severance expenses (4)

 

 

142

 

 

(42) to 358

 

 

2,160

 

 

100 to 500

Non-core operating expenses (5)

 

 

4

 

 

(4)

 

 

2,588

 

 

Gain on sale of certain recovery contracts (7)

 

 

 

 

 

 

(2,403

)

 

Adjusted EBITDA

 

$

319

 

 

$

1,681 to 3,681

 

$

11,896

 

 

$

2,000 to 4,000

(1)

Represents interest expense and amortization of debt issuance costs related to our Credit Agreement and Prior Credit Agreement.

(2)

Represents amortization of intangibles related to the acquisition of Performant by an affiliate of Parthenon Capital Partners in 2004.

(3)

Represents amortization of debt issuance costs related to our Credit Agreement and Prior Credit Agreement.

(4)

Represents severance expenses incurred in connection with a reduction in force for our non-healthcare recovery services.

(5)

Represents professional fees related to strategic corporate development activities.

(6)

Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.

(7)

Represents gain on the sale of certain non-healthcare recovery contracts in 2021.

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES

Reconciliation of Non-GAAP Results

(In thousands, except per share amount)

(Unaudited)

 

We are providing the following historical breakdown of the quarterly and annual revenue contributions under the new contribution breakdowns of our healthcare revenue results for the three months ended March 31, 2022, and for the years ended December 31, 2021 and 2020:

 

 

 

For the Three

Months Ended

 

 

March 31, 2022

 

 

(in thousands)

Eligibility-based

 

$

14,215

Claims-based

 

 

9,149

 

Healthcare Total

 

 

23,364

 

Recovery

 

 

118

 

Customer Care / Outsourced Services

 

 

3,601

 

Total

 

$

27,083

 

 

 

For the Three Months Ended

 

For the Year Ended

 

 

March 31, 2021

 

June 30, 2021

 

September 30, 2021

 

December 31, 2021

 

December 31, 2021

 

 

(in thousands)

Eligibility-based

 

$

7,911

 

$

11,577

 

$

12,727

 

$

16,061

 

$

48,276

Claims-based

 

 

5,375

 

 

 

7,025

 

 

 

7,280

 

 

 

9,498

 

 

 

29,178

 

Healthcare Total

 

 

13,286

 

 

 

18,602

 

 

 

20,007

 

 

 

25,559

 

 

 

77,454

 

Recovery

 

 

14,491

 

 

 

11,091

 

 

 

5,490

 

 

 

2,333

 

 

 

33,405

 

Customer Care / Outsourced Services

 

 

3,613

 

 

 

3,149

 

 

 

3,085

 

 

 

3,687

 

 

 

13,534

 

Total

 

$

31,390

 

 

$

32,842

 

 

$

28,582

 

 

$

31,579

 

 

$

124,393

 

 

 

For the Three Months Ended

 

For the Year Ended

 

 

March 31, 2020

 

June 30, 2020

 

September 30, 2020

 

December 31, 2020

 

December 31, 2020

 

 

(in thousands)

Eligibility-based

 

$

10,949

 

$

11,292

 

$

13,480

 

$

14,126

 

$

49,847

Claims-based

 

 

6,575

 

 

 

3,301

 

 

 

4,086

 

 

 

4,739

 

 

 

18,701

 

Healthcare Total

 

 

17,524

 

 

 

14,593

 

 

 

17,566

 

 

 

18,865

 

 

 

68,548

 

Recovery

 

 

24,265

 

 

 

16,167

 

 

 

15,443

 

 

 

17,521

 

 

 

73,396

 

Customer Care / Outsourced Services

 

 

4,099

 

 

 

3,025

 

 

 

3,219

 

 

 

3,650

 

 

 

13,993

 

Total

 

$

45,888

 

 

$

33,785

 

 

$

36,228

 

 

$

40,036

 

 

$

155,937

 

 

Richard Zubek

Investor Relations

925-960-4988

investors@performantcorp.com

Source: Performant Financial Corporation

FAQ

What were the total revenues for Performant Financial Corporation in Q1 2022?

Total revenues for Q1 2022 were $27.1 million.

How did healthcare revenues perform in Q1 2022 for PFMT?

Healthcare revenues grew by 76% to $23.4 million in Q1 2022.

What is the adjusted EBITDA for Performant Financial in Q1 2022?

The adjusted EBITDA for Q1 2022 was $0.3 million.

What is the projected healthcare revenue for PFMT in 2022?

The company anticipates healthcare revenues of $92 to $96 million for 2022.

What is the net loss reported by Performant Financial in Q1 2022?

The net loss in Q1 2022 was approximately $1.7 million.

Performant Healthcare, Inc.

NASDAQ:PFMT

PFMT Rankings

PFMT Latest News

PFMT Stock Data

278.72M
68.68M
8.11%
84.37%
1.17%
Specialty Business Services
Services-miscellaneous Business Services
Link
United States of America
PLEASANTON